Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07100418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 3, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 200 to confirmed 224 · Site details revisedv3 Show 2 more changesShow less
    • Enrollment target: estimated 200 to confirmed 224
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Aug 2025 to Aug 12, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Aug 2025 to Aug 12, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is being conducted to evaluate the efficacy and safety of HRS-7249 for patients with hyperlipidemia, and to explore the reasonable dosage of HRS-7249 for patients with hyperlipidemia.
Trial Details
NCT Number NCT07100418
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Hyperlipidemia
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov